Blog
About

2
views
0
recommends
+1 Recommend
0 collections
    0
    shares
      • Record: found
      • Abstract: found
      • Article: not found

      Cost-Effectiveness and Value of Information of Erlotinib, Afatinib, and Cisplatin-Pemetrexed for First-Line Treatment of Advanced EGFR Mutation-Positive Non-Small-Cell Lung Cancer in the United States.

      Read this article at

      ScienceOpenPublisherPubMed
      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          To determine the cost-effectiveness of tyrosine kinase inhibitors erlotinib or afatinib, or chemotherapy cisplatin-pemetrexed, for first-line treatment of advanced epithelial growth factor receptor mutation-positive non-small-cell lung cancer in the United States. We also assessed the expected benefit of further research to reduce uncertainty regarding which treatment is optimal.

          Related collections

          Author and article information

          Journal
          Value Health
          Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research
          Elsevier BV
          1524-4733
          1098-3015
          Sep 2015
          : 18
          : 6
          Affiliations
          [1 ] Department of Clinical Pharmacy, University of California, San Francisco, CA, USA. Electronic address: tingj@pharmacy.ucsf.edu.
          [2 ] Department of Clinical Pharmacy, University of California, San Francisco, CA, USA.
          [3 ] Department of Clinical Pharmacy, University of California, San Francisco, CA, USA; Department of Medicine, University of California, San Francisco, CA, USA.
          Article
          S1098-3015(15)01934-8
          10.1016/j.jval.2015.04.008
          26409604

          Comments

          Comment on this article